State Street Corp. Updates Passive Stake in Fate Therapeutics
Ticker: FATE · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still holds FATE THERAPEUTICS shares, signaling institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, filed an amended Schedule 13G on January 22, 2024, disclosing its ownership of FATE THERAPEUTICS INC common stock as of December 31, 2023. This filing indicates State Street's passive investment in Fate Therapeutics, a biotechnology company, and is an update to their previous disclosures. This matters to investors because it shows a significant institutional holder maintains a position, which can signal confidence in the company's long-term prospects, even if the exact percentage of ownership isn't detailed in the provided snippet.
Why It Matters
This filing confirms State Street Corporation's continued passive investment in Fate Therapeutics, which can be a positive signal for other investors as large institutional holdings often imply a degree of confidence in the company's stability or future growth.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor, indicating a passive stake and not suggesting any immediate risks or major changes.
Analyst Insight
Investors should note that a major institutional investor like State Street Corporation maintains a position in FATE THERAPEUTICS INC, which could be seen as a vote of confidence, but this filing alone doesn't provide details on the percentage of ownership or any changes from previous filings, so further investigation into State Street's specific holdings and the company's fundamentals is warranted.
Key Numbers
- 31189P102 — CUSIP Number (identifies FATE THERAPEUTICS INC common stock)
- 12/31/2023 — Date of Event (the snapshot date for the reported ownership)
- 005-87649 — SEC File Number (identifies FATE THERAPEUTICS INC's registration with the SEC)
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- FATE THERAPEUTICS INC (company) — the subject company whose common stock is being reported
- 0000093751-24-000067 (dollar_amount) — accession number for the filing
- 12/31/2023 (date) — date of event which requires filing of this statement
- 04-2456637 (dollar_amount) — IRS Identification Number for State Street Corporation
Forward-Looking Statements
- State Street Corporation will continue to hold a significant, passive stake in FATE THERAPEUTICS INC. (State Street Corporation) — medium confidence, target: Q1 2025
FAQ
What is the purpose of this SC 13G/A filing?
This SC 13G/A filing is an amendment to a Schedule 13G, indicating that State Street Corporation is updating its disclosure regarding its passive ownership of FATE THERAPEUTICS INC common stock as of December 31, 2023, under Rule 13D-1(B).
Who is the reporting person in this filing?
The reporting person is STATE STREET CORPORATION, with an I.R.S. Identification No. of 04-2456637, located at 1 Congress Street, Suite 1, Boston, MA 02114.
What is the subject company of this filing?
The subject company is FATE THERAPEUTICS INC, a biotechnology company with CIK 0001434316, located at 12278 Scripps Summit Drive, San Diego, CA 92131.
What is the 'Date of Event' that triggered this filing?
The 'Date of Event which requires filing of this statement' is December 31, 2023, meaning the ownership data reported reflects the holdings as of that date.
Under which specific SEC rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13D-1(B), as indicated by the 'X' next to '(X) RULE 13D-1 (B)' on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding FATE THERAPEUTICS INC (FATE).